Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial von Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W

Volltext

Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply von Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W

Volltext

Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/... von Lamarca, Angela, Palmer, Daniel H., Wasan, Harpreet Singh, Ross, Paul J., Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Hobbs, Claire, Wilkinson, Lorna, Macdonald, Timothy, Hartley, Claire, Ryder, David, Bridgewater, John A., Valle, Juan W.

Volltext

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) w... von Lamarca, Angela, Palmer, Daniel H., Wasan, Harpreet Singh, Ross, Paul J., Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Waters, Justin S., Hobbs, Claire, Barber, Safia, Ryder, David, Ramage, John, Davies, Linda M, Bridgewater, John A., Valle, Juan W.

Volltext

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial von Lamarca, A, Palmer, DH, Wasan, HS, Ross, PJ, Ma, YT, Arora, A, Falk, S, Gillmore, R, Wadsley, J, Patel, K, Anthoney, A, Maraveyas, A, Iveson, T, Waters, JS, Hobbs, C, Barber, S, Ryder, WD, Ramage, J, Davies, LM, Bridgewater, JA, Valle, JW, Advanced Biliary Cancer Working Group

Volltext bestellen